| Patent Number |
Title Of Patent |
Date Issued |
| 7030123 |
Indole derivatives with vascular damaging activity |
April 18, 2006 |
| The invention provides a compound of Formula (I). ##STR00001## Wherein R1, R2, R3, R10 and R11 have the meanings given in the description. Such compounds are predicted to cause the selective destruction of tumour vasculature. They may therefore be used to inhibit and/or reverse, and/or |
| 6436691 |
Chemical compounds |
August 20, 2002 |
| Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor |
| 6339070 |
Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety |
January 15, 2002 |
| The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell i |
| 5985281 |
Chemical compounds |
November 16, 1999 |
| A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprisin |
| 5665357 |
Antibodies recognizing tumor associated antigen CA 55.1 |
September 9, 1997 |
| Antibodies which recognize a tumor related antigen designated CA55.1 such as hybridoma 55.1 deposited as ECACC deposit no. 93081901 in which the complementarity determining regions have the following sequences:a) heavy chainCDR1 G Y W I H (SEQ ID NO: 27)CDR2 E V N P S T G R S D Y N E K F K N |
